Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer headquartered in Ningbo, China, has announced the successful completion of the first clinical implantation surgery using its transjugular tricuspid valve replacement product, LuX-Valve Plus, in Brazil. This milestone marks a significant advancement for the company in the field of minimally invasive cardiac procedures.
Post-surgery assessments confirmed that the implanted valve demonstrated stability, with no signs of regurgitation or perivalvular leakage. Additionally, the patient’s mitral regurgitation was observed to be reduced, indicating the procedure’s effectiveness. The patient’s clinical manifestations, cardiac function, and overall quality of life showed notable improvements following the surgery.
Jenscare is progressing with regulatory steps for LuX-Valve Plus, including advancing marketing filings in China, conducting CE certified clinical studies in Europe, and initiating regulatory clinical studies in the United States. These efforts reflect the company’s commitment to global expansion and to providing innovative solutions for patients suffering from structural heart diseases.
The successful surgery and subsequent patient improvements underscore the potential impact of Jenscarce’s technology on the treatment of tricuspid valve diseases and highlight the company’s role as an innovator in the cardiac device market.- Flcube.com
